Drug Eluting Balloon Market (Product - Coronary Drug Eluting Balloon, Peripheral Drug Eluting Balloon; Drug Coating Technology - Paccocath, FreePac, TransPax, EnduraCoat) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2030

Drug-eluting balloons refer to semi-compliant angioplasty balloons that are coated with anti-proliferative medications and are dispersed in the walls of blood arteries following balloon inflation, which is typically done at minimal pressures. These balloons greatly reduce cellularity and remove the need for repeated vascularization. The increasing vascular disease rates, increased product advancements, and rising elderly population are all contributing to increasing demand for the drug-eluting balloon in the healthcare industry. However, the global drug eluting balloon market is predicted to develop slowly owing to the high cost of processes and goods, as well as tight regulatory rules.

Increasing Initiatives from Government and Private Players to Drives Sales Opportunities in the Market

Over the last decade, the healthcare infrastructure has seen significant changes as technology has advanced and healthcare research has exploded. Some of the causes driving demand for drug eluting balloon catheters are increasing incidences of obesity, an aging population, and a rise in occurrence of coronary artery disease. Stents that are utilized with a balloon catheter are referred to as balloon expandable stents, as opposed to self-expandable stents, which are often composed of nitinol alloy.

The global drug eluting balloon market is also benefiting from the increasing adoption of angioplasty balloons for patients who do not gain from percutaneous coronary intervention (PCI). Governments and other organizations are increasingly supporting research and providing financing to further develop drug eluting balloon catheters.

Drug eluting devices are used to lessen the incidence of restenosis and are most commonly connected with cardiac problems. Over the next 10 years, the market for peripheral drug-coated balloon catheters is expected to expand at a stable growth rate. As the benefits of drug-eluting balloon catheters are discovered and treatments become more inexpensive, the use of these catheters for peripheral artery operations is expected to rise.

Demand for coronary artery disease drug eluting balloon catheters is expected to account for over 80% of market share when it comes to value in the indication segment. Despite a small market share, the demand for drug-eluting balloon catheters for peripheral vascular disease is expected to grow at a stable CAGR in the years to come. With additional angioplasty balloons being studied and manufactured, sales of peripheral drug-coated balloon catheters are expected to rise as well.

Cardiovascular illnesses are a serious public-health concern. Peripheral artery disease (PAD) is a prevalent kind of peripheral vascular disease that affects persons over the age of 65 years. PAD causes the walls of arteries to thin, slowing blood flow. Although it most usually affects the peripheral areas, it can also damage the arteries that bring blood from the head to the heart, kidneys, and stomach. Given the rising prevalence of cardiovascular illnesses, it's critical to comprehend the elements that influence the extent of the diseases and the effective treatment choices available. A number of governmental and private players are making serious efforts through various initiatives in reducing the prevalence of cardiovascular disease. Governments  as well as physicians and in industrialized nations have begun to inform the common people about PAD.

Every September, medical device firms, doctors, payers, and health care providers in the U.S. commemorate 'PAD Awareness Month.' During the awareness initiative, they strive to inform people about the ill effects of PAD and how to manage it. Several government agencies are funding research groups to help them produce drug-eluting balloons that are more successful in treating cardiovascular disorders. In the forthcoming years, this is anticipated to boost the global drug eluting balloon market.

North America and Asia Pacific to Lead the Market due to High Prevalence of Cardiovascular Illnesses

North America region is expected to account for a prominent share in the global drug eluting balloon market. High rate of treatment as well as diagnosis of cardiovascular illnesses and increasing spending on healthcare is anticipated to augur well for the drug eluting balloon market in North America. Besides, greater penetration of innovative products along with favorable reimbursement policies is expected to drive sales growth in the regional market.

However, the expiration of TPT reimbursement on medication eluting balloons in December 2017 and ' tight regulatory system in the U.S. are expected to limit the drug eluting balloon market's growth in North America over the next two to three years. Due to the growing senior population, need for higher quality of care, and rise in the prevalence of cardiovascular illnesses in the area, the drug eluting balloon market in Asia Pacific is expected to provide substantial potential throughout the projected period.

The global drug eluting balloon market has been segmented as follows:

Product

• Coronary Drug Eluting Balloon
• Peripheral Drug Eluting Balloon
• Others

Technology

• Paccocath
• FreePac
• TransPax
• EnduraCoat
• Others

End-user

• Hospitals and Ambulatory Surgery Centers
• CATH Labs
• Others

Region

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia & New Zealand
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
• GCC Countries
• South Africa
• Israel
• Rest of Middle East & Africa

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Drug Eluting Balloon Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Type Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
            4.3.2. Restraints
            4.3.3. Opportunities
     4.4. Global Drug Eluting Balloon Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)

5. Market Outlook
     5.1. Reimbursement Scenario
     5.2. Cardiovascular Disease Prevalence
     5.3. Key Mergers & Acquisitions 
     5.4. Key Market Trends

6. Global Drug Eluting Balloon Market Analysis and Forecast, by Product Type 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Market Value Forecast, by Product Type, 2016–2026
            6.3.1. Coronary Drug Eluting Balloon
            6.3.2. Peripheral Drug Eluting Balloon 
            6.3.3 Others
     6.4. Market Attractiveness, by Product Type

7. Global Drug-Eluting Balloon Market Analysis and Forecast, by Drug Coating Technology 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Market Value Forecast, by Drug Coating Technology, 2016–2026
            7.3.1. Paccocath
            7.3.2. FreePac
            7.3.3. TransPax
            7.3.4. EnduraCoat
            7.3.5. Others
     7.4. Market Attractiveness, by Drug Coating Technology

8. Global Drug Eluting Balloon Market Analysis and Forecast, by End-user 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments
     8.3. Market Value Forecast, by End-user, 2016–2026
            8.3.1. Hospitals & Ambulatory Surgical Centers 
            8.3.2. Cath Labs 
            8.3.3. Others
     8.4. Market Attractiveness, by End-user

9. Global Drug Eluting Balloon Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Market Attractiveness, by Country/Region

10. North America Drug Eluting Balloon Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. Market Value Forecast, by Product Type, 2016–2026
            10.2.1. Coronary Drug Eluting Balloon
            10.2.2. Peripheral Drug Eluting Balloon
            10.2.3. Others
     10.3. Market Value Forecast, by Drug Coating Technology, 2016–2026
            10.3.1. Paccocath
            10.3.2. FreePac 
            10.3.3. TransPax
            10.3.4. EnduraCoat 
            10.3.5. Others
     10.4. Market Value Forecast, by End-user, 2016–2026
            10.4.1. Hospitals & Ambulatory Surgical Centers
            10.4.2. Cath Labs 
            10.4.3. Others
     10.5. Market Value Forecast, by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6. Market Attractiveness Analysis 
            10.6.1. By Product Type 
            10.6.2. By Drug Coating Technology
            10.6.3. By End-user 
            10.6.4. By Country

11. Europe Drug Eluting Balloon Market Analysis and Forecast
     11.1.Introduction
            11.1.1. Key Findings
     11.2.Market Value Forecast, by Product Type, 2016–2026
            11.2.1. Coronary Drug Eluting Balloon
            11.2.2. Peripheral Drug Eluting Balloon
            11.2.3 Others
     11.3.Market Value Forecast, by Drug Coating Technology, 2016–2026
            11.3.1. Paccocath
            11.3.2. FreePac 
            11.3.3. TransPax
            11.3.4. EnduraCoat 
            11.3.5. Others
     11.4.Market Value Forecast, by End-user, 2016–2026
            11.4.1. Hospitals & Ambulatory Surgical Centers
            11.4.2. Cath Labs 
            11.4.3. Others
     11.5.Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Italy
            11.5.5. Spain
            11.5.6. Rest of Europe
     11.6.Market Attractiveness Analysis 
            11.6.1. By Product Type 
            11.6.2. By Drug Coating Technology
            11.6.3. By End-user 
            11.6.4. By Country/Sub-region

12. Asia Pacific Drug Eluting Balloon Market Analysis and Forecast
     12.1.Introduction
            12.1.1. Key Findings
     12.2.Market Value Forecast, by Product Type, 2016–2026
            12.2.1. Coronary Drug Eluting Balloon
            12.2.2. Peripheral Drug Eluting Balloon
            12.2.3. Others
     12.3.Market Value Forecast, by Drug Coating Technology, 2016–2026
            12.3.1. Paccocath
            12.3.2. FreePac 
            12.3.3. TransPax
            12.3.4. EnduraCoat 
            12.3.5. Others
     12.4.Market Value Forecast, by End-user, 2016–2026
            12.4.1. Hospitals & Ambulatory Surgical Centers
            12.4.2. Cath Labs 
            12.4.3. Others
     12.5.Market Value Forecast, by Country/Sub-region, 2016–2026
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6.Market Attractiveness Analysis 
            12.6.1. By Product Type 
            12.6.2. By Drug Coating Technology
            12.6.3. By End-user 
            12.6.4. By Country

13. Latin America Drug Eluting Balloon Market Analysis and Forecast
     13.1.Introduction
            13.1.1. Key Findings
     13.2.Market Value Forecast, by Product Type, 2016–2026
            13.2.1. Coronary Drug Eluting Balloon
            13.2.2. Peripheral Drug Eluting Balloon
            13.2.3 Others
     13.3.Market Value Forecast, by Drug Coating Technology, 2016–2026
            13.3.1. Paccocath
            13.3.2. FreePac 
            13.3.3. TransPax
            13.3.4. EnduraCoat 
            13.3.5. Others
     13.4.Market Value Forecast, by End-user, 2016–2026
            13.4.1. Hospitals & Ambulatory Surgical Centers
            13.4.2. Cath Labs 
            13.4.3. Others
     13.5.Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6.Market Attractiveness Analysis 
            13.6.1. By Product Type 
            13.6.2. By Drug Coating Technology
            13.6.3. By End-user 
            13.6.4. By Country/Sub-region

14. Middle East & Africa Drug-Eluting Balloon Market Analysis and Forecast
     14.1.Introduction
            14.1.1. Key Findings
     14.2.Market Value Forecast, by Product Type, 2016–2026
            14.2.1. Coronary Drug Eluting Balloon
            14.2.2. Peripheral Drug Eluting Balloon
            14.2.3 Others
     14.3.Market Value Forecast, by Drug Coating Technology, 2016–2026
            14.3.1. Paccocath
            14.3.2. FreePac 
            14.3.3. TransPax
            14.3.4. EnduraCoat 
            14.3.5. Others
     14.4.Market Value Forecast, by End-user, 2016–2026
            14.4.1. Hospitals & Ambulatory Surgical Centers
            14.4.2. Cath Labs 
            14.4.3. Others
     14.5.Market Value Forecast, by Country/Sub-region, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Israel
            14.5.4. Rest of Middle East & Africa 
     14.6.Market Attractiveness Analysis 
            14.6.1. By Product Type 
            14.6.2. By Drug Coating Technology
            14.6.3. By End-user 
            14.6.4. By Country/Sub-region

15. Competition Landscape
     15.1.Market Player – Competition Matrix (by Tier and Size of companies)
     15.2.Market Share Analysis, by Company (2017)
     15.3. Competitive Business Strategies
     15.4. Company Profiles
            15.4.1. Bayer AG
                      15.4.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.1.2. Product Portfolio
                      15.4.1.3. SWOT Analysis
                      15.4.1.4. Strategic Overview
                      15.4.1.5. Financial Overview
            15.4.2. Medtronic
                      15.4.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.2.2. Product Portfolio
                      15.4.2.3. SWOT Analysis
                      15.4.2.4. Strategic Overview
                      15.4.2.5. Financial Overview
            15.4.3. B. Braun Melsungen AG
                      15.4.3.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.3.2. Product Portfolio
                      15.4.3.3. SWOT Analysis
                      15.4.3.4. Strategic Overview
                      15.4.3.5. Financial Overview
            15.4.4. Cook Medical, Inc.
                      15.4.4.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.4.2. Product Portfolio
                      15.4.4.3. SWOT Analysis
                      15.4.4.4. Strategic Overview
                      15.4.4.5. Financial Overview
            15.4.5. Boston Scientific Corporation
                      15.4.5.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.5.2. Product Portfolio
                      15.4.5.3. SWOT Analysis
                      15.4.5.4. Strategic Overview
                      15.4.5.5. Financial Overview
            15.4.6. Becton, Dickinson and Company
                      15.4.6.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.6.2. Product Portfolio
                      15.4.6.3. SWOT Analysis
                      15.4.6.4. Strategic Overview
                      15.4.6.5. Financial Overview
            15.4.7. EuroCor
                      15.4.7.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.7.2. Product Portfolio
                      15.4.7.3. SWOT Analysis
                      15.4.7.4. Strategic Overview
                      15.4.7.5. Financial Overview
            15.4.8. Terumo Corporation
                      15.4.8.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.8.2. Product Portfolio
                      15.4.8.3. SWOT Analysis
                      15.4.8.4. Strategic Overview
                      15.4.8.5. Financial Overview
            15.4.9. Koninklijke Philips N.V
                      15.4.9.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.9.2. Product Portfolio
                      15.4.9.3. SWOT Analysis
                      15.4.9.4. Strategic Overview
                      15.4.9.5. Financial Overview
            15.4.10. Other Prominent Players
                      15.4.10.1. Company Overview (HQ, Business Segments, Employee Strength)
                      15.4.10.2. Product Portfolio
                      15.4.10.3. SWOT Analysis
                      15.4.10.4. Strategic Overview
                      15.4.10.5. Financial Overview